Randomized Phase II JANUS Study of Atacicept in Patients With IgA Nephropathy and Persistent Proteinuria

Jonathan Barratt,James Tumlin,Yusuke Suzuki,Amy Kao,Aida Aydemir,Kishore Pudota,Hulin Jin, Hans Gühring,Gerald Appel

Kidney International Reports（2022）

引用 21|浏览5

暂无评分

摘要

Atacicept has an acceptable safety profile in patients with IgAN and is effective at reducing the levels of pathogenic factor Gd-IgA1, with potential improvements in proteinuria and renal function.

查看译文

关键词

APRIL/BLyS inhibitor,atacicept,galactose-deficient IgA1,IgA nephropathy,phase II,proteinuria

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要